Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Congress shields FDA whistleblowers

Executive Summary

The House of Representatives passes an amendment March 14 to H.R. 985, which shields whistleblowers who report tampering with government scientific investigations. The amendment, proposed by Rep. Bart Stupak, D-MI., will "enhance whistleblower protection by including in the list of reportable actions any attempt to suppress the right of government scientists to publish or announce their findings in peer reviewed journals or public meetings with their fellow scientists." Stupak cites a Union of Concerned Scientists survey, finding that of the 997 FDA scientists who responded, 36 percent did not feel they could openly express concerns within the agency about public health without fear of retaliation (1"The Pink Sheet" July 24, 2006, p. 16)...

You may also be interested in...

FDA Scientists Fear Retaliation For Conveying Health Risks, Survey Finds

FDA scientists fear retaliation for expressing health concerns to the public, according to results of a Union of Concerned Scientists survey released July 20

The Top Five (Non-COVID) Pharma Stories Of 2020

The (virtual) doors closing on the J.P. Morgan Healthcare Conference is the sign for the biopharma industry that the new year has truly started, but before we get too far into 2021, Scrip has taken a look at five of the biggest non-COVID-19 story themes of 2020 in no particular order.

The Race To Vaccinate The World Against COVID-19

Our graphic tracker of key developments from emergency authorized vaccines, the global roll-out, and late-stage vaccine candidates.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts